MRVI

In a report released on November 4, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Maravai Lifesciences Holdings (MRVI - Research Report), with a price target of $20.00. The company's shares closed yesterday at $14.16.According to TipRanks, Arias is an analyst with an average return of -1.5% and a 47.33% success rate. Arias covers the Healthcare sector, focusing on stocks such as Illumina, Thermo Fisher, and 10x Genomics.Currently, the analyst consensus on Maravai Lifesciences Holdings is a Strong Buy with an average price target of $24.33, which is a 71.82% upside from current levels.
https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-maravai-lifesciences-holdings-mrvi?utm_source=advfn.com&utm_medium=referral